On behalf of the institute our laboratory is a part of the COST action CA17116

Stem cells hold great promise in the evolving field of regenerative medicine, and there are many sources, which they can be obtained from. Over the past decade different perinatal (Pn) tissues have been shown to harbor a vast array of stem cells with therapeutic potential. This relatively new field of research is rapidly expanding, and its relevance is supported by the recent emergence of clinical trials in Europe and worldwide.

There are, however, many issues that need to be addressed to ensure optimal research outcome and clinical experimentation data interpretation. These issues range from the need to come to a consensus on nomenclature and optimal techniques for isolation, characterization, and cryopreservation, to more advanced issues such as collating data and expertise towards an understanding and exploitation of the mechanisms and therapeutic effects of perinatal derivatives. There is also a necessity to identify gaps in knowledge and how collaborative research can address them.

Therefore, this COST Action will unite a currently fragmented critical mass of academic, clinical, and industry expertise to enhance both basic understanding and translational potential of perinatal derivatives. The Action will develop a platform for the exchange of concepts, methods, and training of young researchers.



Areas of Expertise Keywords
  • Medical biotechnology: Gene therapy, stem cell therapy, regenerative medicine for medical biotechnology
  • regenerative medicine
  • translational medicine
  • stem cells
  • human term placenta-derived cells
  • amniotic fluid



Main Proposer: IT

Network of Proposers: AT, BE, BG, CH, ES, FI, FR, IE, IL, IT, LU, PL, PT, RO, SE, SI, UK

Main and secondary proposers: 24% ECI / 36% Women / 35% ITC



Near Neighbor Country: Ukraine

International Partner Country (IPC): China, India, Iran, Japan, Saudi Arabia, United States



SMEs: Belgium, Finland, Israel, Italy, Luxembourg, Slovenia, Ukraine


Please write on this email address for further collaboration